JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 31, 2006; DOI: 10.1124/jpet.106.102780


0022-3565/06/3183-1102-1107$20.00
JPET 318:1102-1107, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.102780v1
318/3/1102    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Endo, H.
Right arrow Articles by Shimokawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Endo, H.
Right arrow Articles by Shimokawa, H.

CARDIOVASCULAR

Reduced Inotropic Effect of Nifekalant in Failing Hearts in Rats

Hideaki Endo, Masahito Miura, Masanori Hirose, Jun Takahashi, Makoto Nakano, Yuji Wakayama, Yoshinao Sugai, Yutaka Kagaya, Jun Watanabe, Kunio Shirato, and Hiroaki Shimokawa

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Class III antiarrhythmic agents have been widely used to suppress ventricular tachyarrhythmias in patients with heart failure because they have been shown to have positive inotropic effects as well. However, it remains to be examined whether those agents also exert positive inotropic effects in failing hearts. We addressed this important issue in a rat model of heart failure. We used Nifekalant as a representative class III antiarrhythmic agent. Four weeks after a s.c. injection of 60 mg/kg monocrotaline (MCT) or vehicle (Ctr) into rats, we obtained trabeculae from right ventricles and measured the developed force and intracellular Ca2+ ([Ca2+]i) by the fura-2 microinjection method. The sarcoplasmic reticulum (SR) Ca2+ content was assessed by the rapid-cooling contracture (RCC) technique. MCT rats exhibited right ventricular hypertrophy induced by pressure overload. The protein expression of SR Ca2+ ATPase type 2 (SERCA2) and the SERCA2/phospholamban ratio in MCT rats was lower with a slower decline of Ca2+ transients and a reduced amplitude of RCCs. Nifekalant concentration-dependently increased the force, peak [Ca2+]i, and the amplitude of RCCs in Ctr rats but not in MCT rats with identical prolongation of the action potential. Under the SR inhibited with cyclopiazonic acid and ryanodine, Nifekalant increased the force in Ctr rats but not in MCT rats. These results indicate that the positive inotropic effects of Nifekalant is reduced in failing hearts, probably due to the depressed SR Ca2+ uptake and reduced reserve of the trans-sarcolemmal Ca2+ transport, warranting a caution in the antiarrhythmic therapy with a class III antiarrhythmic agent in heart failure.


Received February 10, 2006; accepted May 30, 2006.

Address correspondence to: Dr. Masahito Miura, Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. E-mail: mmiura{at}cardio.med.tohoku.ac.jp







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.